Sensei Biotherapeutics (NASDAQ:FTH) Now Covered by TD Cowen

Key Points

• TD Cowen initiated coverage of Sensei Biotherapeutics with a “buy” rating. The company has an overall “Moderate Buy” consensus rating and an average analyst price target of $55.
• Sensei shares rose 0.5% to $39.41, giving the company a market capitalization of approximately $1.02 billion. The stock has traded between $7.45 and $42.14 over the past year.
• Insiders and institutional investors have been buying shares. Insiders purchased 49,494 shares worth about $1.19 million in the past 90 days, while hedge funds and other institutions currently own 10.5% of the stock.

Equities research analysts at TD Cowen started coverage on shares of Sensei Biotherapeutics (NASDAQ:FTH - Get Free Report) in a report issued on Wednesday, Briefing.com reports. The brokerage set a "buy" rating on the stock.

Several other brokerages have also recently weighed in on FTH. BTIG Research restated a "buy" rating and set a $55.00 target price on shares of Sensei Biotherapeutics in a report on Thursday, July 16th. JonesTrading began coverage on Sensei Biotherapeutics in a research report on Tuesday, August 4th. They set a "buy" rating and a $55.00 price objective on the stock. Oppenheimer assumed coverage on Sensei Biotherapeutics in a research note on Tuesday, July 28th. They set an "outperform" rating and a $60.00 price objective on the stock. HC Wainwright restated a "buy" rating and issued a $60.00 target price on shares of Sensei Biotherapeutics in a report on Tuesday, August 11th. Finally, Citigroup initiated coverage on Sensei Biotherapeutics in a research note on Friday, May 22nd. They issued a "buy" rating and a $55.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Sensei Biotherapeutics has an average rating of "Moderate Buy" and an average target price of $55.00.

Sensei Biotherapeutics Trading Up 0.5%

Shares of NASDAQ:FTH traded up $0.20 during trading on Wednesday, reaching $39.41. The stock had a trading volume of 7,240 shares, compared to its average volume of 214,615. The stock has a fifty day moving average of $30.48. The company has a market cap of $1.02 billion, a PE ratio of -0.28 and a beta of -0.28. Sensei Biotherapeutics has a 1-year low of $7.45 and a 1-year high of $42.14.

Sensei Biotherapeutics (NASDAQ:FTH - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($2.84) earnings per share for the quarter, beating analysts' consensus estimates of ($5.04) by $2.20. Research analysts expect that Sensei Biotherapeutics will post -13.18 earnings per share for the current year.

Insider Transactions at Sensei Biotherapeutics

In related news, CFO Brian C. Stephenson purchased 9,391 shares of the company's stock in a transaction on Wednesday, June 24th. The stock was acquired at an average cost of $26.13 per share, for a total transaction of $245,386.83. Following the completion of the transaction, the chief financial officer directly owned 26,804 shares in the company, valued at approximately $700,388.52. The trade was a 53.93% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Anand Kiran Parikh acquired 2,806 shares of the business's stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average price of $19.76 per share, for a total transaction of $55,446.56. Following the acquisition, the chief executive officer directly owned 764,234 shares in the company, valued at approximately $15,101,263.84. This trade represents a 0.37% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired 49,494 shares of company stock worth $1,188,822 in the last ninety days. 7.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Sensei Biotherapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Vivo Capital LLC purchased a new position in Sensei Biotherapeutics in the 1st quarter valued at approximately $22,758,000. Alyeska Investment Group L.P. purchased a new stake in Sensei Biotherapeutics during the 2nd quarter worth about $3,610,000. Stempoint Capital LP purchased a new stake in Sensei Biotherapeutics during the 1st quarter worth about $4,188,000. Bank of America Corp DE raised its position in Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company's stock valued at $1,041,000 after purchasing an additional 32,719 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of Sensei Biotherapeutics by 178.2% in the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company's stock valued at $1,010,000 after buying an additional 20,525 shares during the period. 10.50% of the stock is currently owned by hedge funds and other institutional investors.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.